Sorafenib. ICORG 06-41, V4

Summary

RATIONALE: Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well sorafenib tosylate works in treating patients with relapsed esophageal cancer and/or stomach cancer.

Timeline

Start

2009-02

Primary completion

2012-11

Completion

—

Drugs

Indications